Royalty Pharma plc (NASDAQ:RPRX) Holdings Lowered by Vanguard Group Inc.

Vanguard Group Inc. decreased its stake in Royalty Pharma plc (NASDAQ:RPRX) by 0.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 37,354,009 shares of the biopharmaceutical company’s stock after selling 231,114 shares during the quarter. Vanguard Group Inc. owned 6.34% of Royalty Pharma worth $952,901,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of RPRX. Advisors Asset Management Inc. acquired a new position in shares of Royalty Pharma in the third quarter worth about $359,000. Cerity Partners LLC lifted its position in shares of Royalty Pharma by 11.1% in the 3rd quarter. Cerity Partners LLC now owns 32,896 shares of the biopharmaceutical company’s stock valued at $931,000 after acquiring an additional 3,291 shares in the last quarter. Daiwa Securities Group Inc. boosted its stake in Royalty Pharma by 10.8% in the 3rd quarter. Daiwa Securities Group Inc. now owns 30,694 shares of the biopharmaceutical company’s stock worth $868,000 after purchasing an additional 3,000 shares during the period. Bank of Montreal Can grew its position in Royalty Pharma by 186.0% during the 3rd quarter. Bank of Montreal Can now owns 445,937 shares of the biopharmaceutical company’s stock worth $12,580,000 after purchasing an additional 290,019 shares in the last quarter. Finally, D.A. Davidson & CO. acquired a new stake in Royalty Pharma during the 3rd quarter valued at $1,300,000. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Royalty Pharma Trading Down 0.9 %

Royalty Pharma stock opened at $31.37 on Friday. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64. Royalty Pharma plc has a 12 month low of $24.05 and a 12 month high of $34.20. The company’s fifty day simple moving average is $32.44 and its 200-day simple moving average is $28.84. The stock has a market cap of $18.08 billion, a P/E ratio of 21.63, a P/E/G ratio of 2.31 and a beta of 0.47.

Royalty Pharma (NASDAQ:RPRX) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. As a group, sell-side analysts forecast that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.

Royalty Pharma Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 10th. Investors of record on Friday, February 21st were issued a $0.22 dividend. The ex-dividend date of this dividend was Friday, February 21st. This represents a $0.88 dividend on an annualized basis and a yield of 2.81%. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.21. Royalty Pharma’s dividend payout ratio is currently 60.69%.

Wall Street Analysts Forecast Growth

RPRX has been the subject of several recent analyst reports. TD Cowen raised Royalty Pharma to a “strong-buy” rating in a research report on Tuesday, December 24th. Citigroup restated a “buy” rating on shares of Royalty Pharma in a research report on Friday. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Royalty Pharma has an average rating of “Buy” and an average target price of $41.60.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.